The Behavioral Toxicity of Monoamine Oxidase-lnhibiting Antidepressants (Q37297970)

19 August 2017

1 reference

title

The behavioral toxicity of monoamine oxidase-inhibiting antidepressants (English)

1 reference

19 August 2017

The Behavioral Toxicity of Monoamine Oxidase-lnhibiting Antidepressants (English)

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60185-4

17 October 2022

author name string

D. L. Murphy

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A18913

17 October 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=18913

17 October 2022

publication date

1 January 1977

1 reference

Advances in pharmacology and chemotherapy

19 August 2017

published in

1 reference

19 August 2017

volume

14

1 reference

19 August 2017

page(s)

71-105

1 reference

Mono-amine oxidase inhibitors, sleep and mood

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

Tranylcypromine: A review

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

Comparison of iproniazid with other amine oxidase inhibitors, including W-1544, JB-516, RO 4-1018, and RO 5-0700

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

A comparative trial of four monoamine oxidase inhibitors on chronic depressives

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

A study of iproniazid treatment in chronic akinetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

Effects of Anti-Depressant Drugs On Psychodynamics

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

The clinical effect of isoniazid and iproniazid in the treatment of pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

Effects of methionine loading on the behavior of schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

Long-term antihypertensive effect of pargyline HCl with and without diuretic sulfonamides

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

The switch process from depression to mania: relationship to drugs which alter brain amines.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

The "switch process" in manic-depressive illness. II. Relationship to catecholamines, REM sleep, and drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

Serotonin and central nervous system function

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

Iproniazid in pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

Toxicity of isonicotinic acid hydrazides in pulmonary tuberculosis; toxicity of isoniazid and iproniazid used alone and in combination with streptomycin or p-aminosalicylic acid

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

THERAPEUTIC EFFICACY OF ANTIDEPRESSANT DRUGS. A REVIEW.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

Clinical and theoretical observations on phenelzine (nardil), an antidepressant agent

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

Monoamine oxidase and cerebral uptake of dopaminergic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

The psychiatric side-effects of iproniazid.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

Further studies on iproniazid phosphate; isonicotinil-isopropyl-hydrazine phosphate marsilid

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

Comparison of antidepressant drugs in depressive illnesses

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

Treatment of hospitalized mental patients with iproniazid.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

A clinical trial of marsilid in psychotic depressed patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

Effect of iproniazid on monoamines and monamine oxidase in human brain.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

STUDIES OF PERIODIC CATATONIA. II. THE URINARY EXCRETION OF PHENOLIC AMINES AND ACIDS WITH AND WITHOUT LOADS OF DIFFERENT DRUGS

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

CLINICAL TRIAL WITH THE MONOAMINO OXIDASE INHIBITOR TRANYLCYPROMINE ON A PSYCHIATRIC CLIENTELE

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

Studies in vivo on the relationship between brain tryptophan, brain 5-HT synthesis and hyperactivity in rats treated with a monoamine oxidase inhibitor and L-tryptophan

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

A comparative study of selected antidepressant medications and EST

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

DIFFERENTIAL RESPONSE OF HOSPITALIZED DEPRESSED PATIENTS TO SOMATIC THERAPY

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

Relationship between the Action of Monoamine Oxidase Inhibitors on the Noradrenaline Uptake System and their Antidepressant Efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

Treatment of previously intractable depressions with tranylcypromine and lithium

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

Overdoses of psychotherapeutic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

Confusional psychosis with residual organic cerebral impairment following isoniazid therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

PARGYLINE AND TRANYLCYPROMINE IN THE TREATMENT OF HOSPITALIZED DEPRESSED PATIENTS

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

Basic Dynamic States in Endogenous Psychoses, with Special Reference to the Pharmacotherapy of Depressive States

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

Acetylator status and response to phenelzine in depressed patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

Brain amine concentrations after monoamine oxidase inhibitor administration.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

A Double-Blind Trial of Phenelzine and Amitriptyline in Depressed Out-Patients. a Possible Differential Effect of the Drugs on Symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

Psychiatric reaction patterns to imipramine

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

Use of pargyline (Eutonyl) in private practice

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

REM sleep and central monoamine oxidase inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

A critical study of isocarboxazid (Marplan) in the treatment of depressed patients

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

Drug-induced mood changes in man. I. Observations on healthy subjects, chronically ill patients, and postaddicts

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

A TRIAL OF FOUR ANTI-DEPRESSANT DRUGS

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

EFFECT OF MONOAMINE-OXIDASE INHIBITORS ON THE CONCENTRATIONS OF 5-HYDROXYTRYPTAMINE IN THE HUMAN BRAIN

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

The effects of pheniprazine on visual imagery in perceptual deprivation

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

A report on the effects of phenelzine (nardil), a monoamine oxidase inhibitor, in depressed patients

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

Mental Effects of L-Dopa

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

Reduced monoamine oxidase activity in blood platelets from bipolar depressed patients

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

Regular induction of hypomania by L-dopa in "bipolar" manic-depressive patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

Monamine oxidase in schizophrenia and other behavioral disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

l-Tryptophan in affective disorders: Indoleamine changes and differential clinical effects

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

Genetic Control of Platelet and Plasma Monoamine Oxidase Activity

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

Application of an objective method for measuring the action of "antidepressant" medications

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

Drug therapy in depressions. Controlled evaluation of imipramine, isocarboxazide, dextroamphetamineamobarbital, and placebo

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

Psychiatric and neurological side-effects of isoniazid and iproniazid.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

THE INFLUENCE OF ACETYLATOR PHENOTYPE ON THE EFFECTS OF TREATING DEPRESSION WITH PHENELZINE.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

Depression subtypes and response to phenelzine, diazepam, and a placebo. Results of a nine hospital collaborative study.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

Changes in primate social behavior after treatment with alpha-methyl-para-tyrosine.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

An Evaluation of Iproniazid (Marsilid) in the Treatment of Depression

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

A controlled trial of phenelzine ("Nardil") in the treatment of severe depressive illness

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

Effects of drugs on human blood platelet and plasma amine oxidase activity in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

The monoamine oxidase inhibitor, phenelzine, in the treatment of depressive -anxiety states. A controlled clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

Chemotherapy compared with electroshock in 104 patients with relapsing psychiatric disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

An evaluation of the effectiveness of isocarboxazid (Marplan) in the depressive syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

Drugs in the Treatment of Depression

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

Antidepressants: comparison of clinical effects in anergic schizophrenia and the depressed states

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

Tuberculosis chemotherapy with hydrazine derivatives of isonicotinic acid

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

A Controlled Study of Lithium vs. Chlorpromazine in Acute Schizophrenics

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

Alterations in the pattern of amine excretion in man produced by a monoamine oxidase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

Central-nervous-system effects of ingestin of L-tryptophan by normal subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

Catecholamines in the brain as mediators of amphetamine psychosis

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

PSYCHOTIC REACTIONS DURING THERAPY WITH PARGYLINE

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

Iproniazid; observations on its use in 30 cases

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

Attenuation of the euphoriant and activating effects of d- and l-amphetamine by lithium carbonate treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

Neurotoxicity of commonly used antineoplastic agents (first of two parts).

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

Schizophreniclike psychotic reactions with administration of isoniazid

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

The efficacy of electroconvulsive therapy, iproniazid and placebo in the treatment of young depressed women.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

A comparison of imipramine, electroconvulsive therapy and placebo in the treatment of depressions

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

Effects of L-tryptophan (a natural sedative) on human sleep.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

Total prolonged drug-induced REM sleep suppression in anxious-depressed patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960185-4

7 January 2021

11

1

529

Boston Collaborative Drug Surveillance Program

publication date

1972

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60185-4

17 October 2022

Pharmacological Reviews

71

16

179

Kopin

1966

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60185-4

Occurrence, transport, and storage of octopamine in human thrombocytes

17 October 2022

series ordinal

96

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60185-4

Advances in biochemical psychopharmacology

17 October 2022

98

12

59

Nies

1974

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60185-4

17 October 2022

Identifiers

0 references

1 reference